Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01752101 · ClinicalTrials.gov registry record
Identification of a Plasma Proteomic Signature for Lung Cancer
A clinical trial, sponsored by Integrated Diagnostics.
- Completed
- Registry status
- 475
- Enrollment target
NCT01752101: Completed study, sponsored by Integrated Diagnostics.
NCT01752101 is a clinical trial that has completed, run by Integrated Diagnostics. The registered enrollment target is 475 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01752101 has completed, sponsored by Integrated Diagnostics.
- COMPLETED
- Registry status
- 475 participants
- Enrollment target
Study Summary
The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.
Primary Outcome
The incidence rate of non-small cell lung cancer in the study population will be correlated to the predictive value of the Sponsor's blood test.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-12 |
What the finished NCT01752101 record still lists
NCT01752101 is an observational study that tracks outcomes without assigning an intervention. The registered 475 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01752101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01752101 about?
NCT01752101 is a clinical study titled "Identification of a Plasma Proteomic Signature for Lung Cancer". The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.
What is the current status of trial NCT01752101?
This trial is currently completed. The enrollment target is 475 participants. The study started on 2012-10. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01752101?
This trial is sponsored by Integrated Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
- NCT05451303 · 475 participants
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
- NCT06892379 · 475 participants · Phase 1
A Study of HS-20110 in Participants With Advanced Solid Tumors
- NCT06754046 · 476 participants · NA
BELIEVE Trial: Bulking vErsus sLing for Treating Stress Urinary IncontinEnce at the Time of Vaginal prolapsE Repair (BELIEVE)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia